Ascentage Pharma Group International (AAPG) Current Deferred Revenue (2023 - 2025)
Historic Current Deferred Revenue for Ascentage Pharma Group International (AAPG) over the last 3 years, with Q2 2025 value amounting to $5.2 million.
- Ascentage Pharma Group International's Current Deferred Revenue changed N/A to $5.2 million in Q2 2025 from the same period last year, while for Jun 2025 it was $5.2 million, marking a year-over-year change of. This contributed to the annual value of $5.1 million for FY2024, which is 9795.57% down from last year.
- Latest data reveals that Ascentage Pharma Group International reported Current Deferred Revenue of $5.2 million as of Q2 2025.
- In the past 5 years, Ascentage Pharma Group International's Current Deferred Revenue ranged from a high of $5.3 million in Q4 2023 and a low of $5.2 million during Q4 2024
- In the last 3 years, Ascentage Pharma Group International's Current Deferred Revenue had a median value of $5.2 million in 2025 and averaged $5.3 million.
- Examining YoY changes over the last 5 years, Ascentage Pharma Group International's Current Deferred Revenue showed a top increase of 217.75% in 2024 and a maximum decrease of 217.75% in 2024.
- Quarter analysis of 3 years shows Ascentage Pharma Group International's Current Deferred Revenue stood at $5.3 million in 2023, then fell by 2.18% to $5.2 million in 2024, then rose by 0.28% to $5.2 million in 2025.
- Its last three reported values are $5.2 million in Q2 2025, $5.2 million for Q4 2024, and $5.3 million during Q4 2023.